NEOPHARM CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24,950 KRW | -3.85% |
|
-1.77% | -3.48% |
| 2023 | NeoPharm CO., LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2019 | NeoPharm CO., LTD. announced that it has received KRW 31.970667276 billion in funding | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 378,127 | 223,279 | 193,952 | 150,156 | 202,163 | 195,125 | - | - |
| Enterprise Value (EV) 2 | 297.3 | 131.4 | 89.46 | 150.2 | 202.2 | 66.72 | 42.62 | 12.92 |
| P/E ratio | 20.6 x | 12.4 x | 10.9 x | 8.82 x | 8.71 x | 8.92 x | 6.8 x | 5.76 x |
| Yield | 1.55% | 2.28% | 2.82% | - | - | 3.01% | 3.01% | 3.01% |
| Capitalization / Revenue | 4.54 x | 2.74 x | 2.21 x | - | 2.08 x | 1.63 x | 1.35 x | 1.18 x |
| EV / Revenue | 3.57 x | 1.61 x | 1.02 x | - | 2.08 x | 0.56 x | 0.29 x | 0.08 x |
| EV / EBITDA | 12.3 x | 5.62 x | 3.74 x | - | 7.51 x | 2.3 x | 1.14 x | 0.3 x |
| EV / FCF | 15.9 x | 7.83 x | 4.19 x | - | - | 2.9 x | 1.44 x | 0.36 x |
| FCF Yield | 6.3% | 12.8% | 23.9% | - | - | 34.5% | 69.7% | 276% |
| Price to Book | 3.58 x | 1.9 x | 1.65 x | - | - | 1.1 x | 0.97 x | 0.84 x |
| Nbr of stocks (in thousands) | 7,821 | 7,821 | 7,821 | 7,821 | 7,821 | 7,821 | - | - |
| Reference price 3 | 48,350 | 28,550 | 24,800 | 19,200 | 25,850 | 24,950 | 24,950 | 24,950 |
| Announcement Date | 07/02/20 | 08/02/21 | 08/02/22 | 15/03/23 | 02/02/24 | - | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 83.24 | 81.63 | 87.93 | - | 97.1 | 120 | 145 | 165 |
| EBITDA 1 | 24.17 | 23.4 | 23.93 | - | 26.93 | 29 | 37.4 | 43.3 |
| EBIT 1 | 22.96 | 21.9 | 22.43 | - | 25.31 | 27.5 | 36 | 42 |
| Operating Margin | 27.58% | 26.83% | 25.51% | - | 26.06% | 22.92% | 24.83% | 25.45% |
| Earnings before Tax (EBT) 1 | 23.54 | 22.94 | 23.84 | - | 29.37 | 29.1 | 38.1 | 45.1 |
| Net income 1 | 19.25 | 18.13 | 17.71 | 17.03 | 23.21 | 23 | 30.1 | 35.6 |
| Net margin | 23.12% | 22.21% | 20.14% | - | 23.9% | 19.17% | 20.76% | 21.58% |
| EPS 2 | 2,345 | 2,296 | 2,265 | 2,177 | 2,968 | 2,797 | 3,668 | 4,335 |
| Free Cash Flow 3 | 18,718 | 16,788 | 21,361 | - | - | 23,000 | 29,700 | 35,700 |
| FCF margin | 22,486.73% | 20,567.31% | 24,293% | - | - | 19,166.67% | 20,482.76% | 21,636.36% |
| FCF Conversion (EBITDA) | 77,444.79% | 71,757.05% | 89,260.7% | - | - | 79,310.34% | 79,411.76% | 82,448.04% |
| FCF Conversion (Net income) | 97,259.48% | 92,594.3% | 120,593.56% | - | - | 100,000% | 98,671.1% | 100,280.9% |
| Dividend per Share 2 | 750.0 | 650.0 | 700.0 | - | - | 750.0 | 750.0 | 750.0 |
| Announcement Date | 07/02/20 | 08/02/21 | 08/02/22 | 15/03/23 | 02/02/24 | - | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 19.45 | 24.15 | 22.35 | 21.48 | 27.21 | 28.22 | 30.5 | 28 | 33.4 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 3.452 | 6.172 | 6.338 | 4.949 | 6.933 | 6.791 | 7.3 | 5.7 | 7.9 |
| Operating Margin | 17.75% | 25.56% | 28.36% | 23.04% | 25.48% | 24.07% | 23.93% | 20.36% | 23.65% |
| Earnings before Tax (EBT) | 4.009 | 6.343 | 6.823 | 5.668 | - | - | - | - | - |
| Net income | 3.104 | 4.847 | 4.924 | 4.599 | - | - | - | - | - |
| Net margin | 15.96% | 20.07% | 22.04% | 21.41% | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 05/11/21 | 08/02/22 | 06/05/22 | 05/08/22 | 02/02/24 | 03/05/24 | - | - | - |
1KRW in Billions
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 80.8 | 91.9 | 104 | - | - | 128 | 153 | 182 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 2 | 18,718 | 16,788 | 21,361 | - | - | 23,000 | 29,700 | 35,700 |
| ROE (net income / shareholders' equity) | 23.3% | 16.2% | 14.3% | - | 15.1% | 13.6% | 15.9% | 16.4% |
| ROA (Net income/ Total Assets) | 19.7% | 14.2% | 12.8% | - | - | 12.2% | 14.1% | 14.6% |
| Assets 1 | 97.83 | 127.9 | 138.2 | - | - | 188.5 | 213.5 | 243.8 |
| Book Value Per Share 3 | 13,515 | 15,052 | 15,052 | - | - | 22,657 | 25,766 | 29,575 |
| Cash Flow per Share | 2,541 | - | - | - | - | - | - | - |
| Capex 1 | 0.51 | 0.29 | 0.32 | - | - | - | - | - |
| Capex / Sales | 0.61% | 0.35% | 0.36% | - | - | - | - | - |
| Announcement Date | 07/02/20 | 08/02/21 | 08/02/22 | 15/03/23 | 02/02/24 | - | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.48% | 144M | |
| +1.18% | 265B | |
| +20.31% | 20.59B | |
| +14.35% | 12.22B | |
| -12.64% | 9.42B | |
| +16.55% | 7.67B | |
| +11.43% | 6.05B | |
| -2.43% | 4.45B | |
| -13.62% | 3.98B | |
| -3.97% | 3.66B |
- Stock Market
- Equities
- A092730 Stock
- Financials NeoPharm CO., LTD.
